Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNDX-5613 + Gilteritinib in R/R FLT3-Mutated AML
NCT06222580Phase 1Recruiting
- Start
- Feb 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revumenib in acute myeloid leukemia (AML). Primary endpoints: Incidence of hematologic adverse events, Incidence of non-hematologic adverse events and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06222580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222580.